Literature DB >> 10752798

Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status.

W Y Huang1, B Newman, R C Millikan, M J Schell, B S Hulka, P G Moorman.   

Abstract

Risk factors were examined for subgroups of breast cancer characterized by estrogen receptor (ER) and progesterone receptor (PR) status. Data from the Carolina Breast Cancer Study, a population-based, North Carolina case-control study of 862 breast cancer cases aged 20-74 years diagnosed during 1993-1996 and 790 controls frequency matched on race and age, were obtained by personal interview. ER and PR status was retrieved from medical records (80%) or was determined in the authors' laboratory (11%) but was missing for 9% of cases. The receptor status distribution was as follows: 53% ER+PR+, 11% ER+PR-, 8% ER-PR+, and 28% ER-PR-. Several hormone-related factors were associated with stronger increased risks for ER+PR+ than for ER-PR- breast cancer: the elevated odds ratios were strongest for ER+PR+ breast cancer among postmenopausal women who had an early age at menarche (odds ratio (OR) = 1.6, 95% confidence interval (CI): 1.0, 2.4), nulliparity/late age at first full-term pregnancy (OR = 1.7, 95% CI: 0.9, 3.2 and OR = 1.6, 95% CI: 1.0, 2.7, respectively), or a high body mass index (OR = 1.6, 95% CI: 0.9, 3.0) and among pre-/perimenopausal women who had a high waist-hip ratio (OR = 1.9, 95% CI: 1.2, 3.1). In contrast, family history of breast or ovarian cancer and medical radiation exposure to the chest produced higher odds ratios for ER-PR- than for ER+PR+ breast cancer, especially among pre-/perimenopausal women.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752798     DOI: 10.1093/oxfordjournals.aje.a010265

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  100 in total

1.  Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.

Authors:  Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Bhaskar V S Kallakury; Catalin Marian; David S Goerlitz; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Causes Control       Date:  2011-04-23       Impact factor: 2.506

Review 2.  The balance between leptin and adiponectin in the control of carcinogenesis - focus on mammary tumorigenesis.

Authors:  Michael E Grossmann; Margot P Cleary
Journal:  Biochimie       Date:  2012-06-20       Impact factor: 4.079

3.  Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women.

Authors:  Lynn Rosenberg; Deborah A Boggs; Lauren A Wise; Lucile L Adams-Campbell; Julie R Palmer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

4.  Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos.

Authors:  Golara Golbaghi; Mohammad Mehdi Haghdoost; Debbie Yancu; Yossef López de Los Santos; Nicolas Doucet; Shunmoogum A Patten; J Thomas Sanderson; Annie Castonguay
Journal:  Organometallics       Date:  2019-01-31       Impact factor: 3.876

5.  Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies.

Authors:  Xuehong Zhang; Donna Spiegelman; Laura Baglietto; Leslie Bernstein; Deborah A Boggs; Piet A van den Brandt; Julie E Buring; Susan M Gapstur; Graham G Giles; Edward Giovannucci; Gary Goodman; Susan E Hankinson; Kathy J Helzlsouer; Pamela L Horn-Ross; Manami Inoue; Seungyoun Jung; Polyna Khudyakov; Susanna C Larsson; Marie Lof; Marjorie L McCullough; Anthony B Miller; Marian L Neuhouser; Julie R Palmer; Yikyung Park; Kim Robien; Thomas E Rohan; Julie A Ross; Leo J Schouten; James M Shikany; Shoichiro Tsugane; Kala Visvanathan; Elisabete Weiderpass; Alicja Wolk; Walter C Willett; Shumin M Zhang; Regina G Ziegler; Stephanie A Smith-Warner
Journal:  Am J Clin Nutr       Date:  2012-01-25       Impact factor: 7.045

6.  Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group.

Authors:  Ellen Chuang; Christos Paul; Arielle Flam; Katherine McCarville; Melissa Forst; Sandra Shin; Linda Vahdat; Alexander Swistel; Rache Simmons; Michael Osborne
Journal:  J Immigr Minor Health       Date:  2012-10

7.  A case-control study of oral contraceptive use and incident breast cancer.

Authors:  Lynn Rosenberg; Yuqing Zhang; Patricia F Coogan; Brian L Strom; Julie R Palmer
Journal:  Am J Epidemiol       Date:  2008-12-13       Impact factor: 4.897

8.  Epidemiology of basal-like breast cancer.

Authors:  Robert C Millikan; Beth Newman; Chiu-Kit Tse; Patricia G Moorman; Kathleen Conway; Lynn G Dressler; Lisa V Smith; Miriam H Labbok; Joseph Geradts; Jeannette T Bensen; Susan Jackson; Sarah Nyante; Chad Livasy; Lisa Carey; H Shelton Earp; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2007-06-20       Impact factor: 4.872

9.  Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Authors:  James J Dignam; Kelly Wieand; Karen A Johnson; Bernard Fisher; Lei Xu; Eleftherios P Mamounas
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

10.  Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry.

Authors:  Fang Fang Zhang; Esther M John; Julia A Knight; Manleen Kaur; Mary Daly; Saundra Buys; Irene L Andrulis; Beth Stearman; Dee West; Mary Beth Terry
Journal:  Breast Cancer Res Treat       Date:  2012-12-06       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.